scholarly journals Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model

Oncotarget ◽  
2016 ◽  
Vol 7 (41) ◽  
pp. 67403-67411 ◽  
Author(s):  
Florian C. Maier ◽  
Julia Schmitt ◽  
Andreas Maurer ◽  
Walter Ehrlichmann ◽  
Gerald Reischl ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Mouse Model ◽  
Ex Vivo ◽  
Emission Tomography ◽  
Luminescence Imaging ◽  
Cerenkov Luminescence Imaging ◽  
Positron Emission

IC-P-024: A novel positron emission tomography contrast agent targeting cathepsin d shows preferential in vivo retention in an Alzheimer's disease mouse model

2015 ◽  
Vol 11 (7S_Part_1) ◽  
pp. P26-P27
Author(s):  
Jonatan A. Snir ◽  
Mojmir Suchy ◽  
Geron A. Bindseil ◽  
Blaine A. Chronik ◽  
Robert H.E. Hudson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Positron Emission Tomography ◽  
Mouse Model ◽  
Contrast Agent ◽  
Cathepsin D ◽  
Emission Tomography ◽  
Positron Emission

O1-02-05: A novel positron emission tomography contrast agent targeting cathepsin d shows preferential in vivo retention in an Alzheimer's disease mouse model

2015 ◽  
Vol 11 (7S_Part_3) ◽  
pp. P128-P128
Author(s):  
Jonatan A. Snir ◽  
Mojmir Suchy ◽  
Geron A. Bindseil ◽  
Blaine A. Chronik ◽  
Robert H.E. Hudson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Positron Emission Tomography ◽  
Mouse Model ◽  
Contrast Agent ◽  
Cathepsin D ◽  
Emission Tomography ◽  
Positron Emission

Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography

Synapse ◽  
2006 ◽  
Vol 60 (4) ◽  
pp. 314-318 ◽  
Author(s):  
Neil Vasdev ◽  
Sridhar Natesan ◽  
Laurent Galineau ◽  
Armando Garcia ◽  
Winston T. Stableford ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Ex Vivo ◽  
Emission Tomography ◽  
In Vivo Evaluation ◽  
Dopamine D2 ◽  
D2 Agonist ◽  
Positron Emission ◽  
Dopamine D2 Agonist

scholarly journals Use of Positron Emission Tomography to Study AT1 Receptor Regulation In Vivo

2001 ◽  
Vol 12 (7) ◽  
pp. 1350-1358
Author(s):  
ZSOLT SZABO ◽  
ROBERT C. SPETH ◽  
P. RANDY BROWN ◽  
LEVENTE KERENYI ◽  
PAN FU KAO ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Receptor Binding ◽  
Ex Vivo ◽  
Sodium Intake ◽  
Plasma Renin ◽  
Emission Tomography ◽  
Dietary Sodium ◽  
Compensatory Mechanism ◽  
Positron Emission

Abstract. Increased sodium intake and enhanced sodium sensitivity are implicated in the pathogenesis of hypertension and in the control of a major regulator of BP, the type 1 angiotensin receptor (AT1 receptor). An in vivo technique to study changes of renal AT1 receptors by dietary sodium was developed that uses positron emission tomography (PET). PET revealed that renal cortical AT1 receptor binding was increased in sodium-loaded compared with sodium-deprived dogs, which correlated with ex vivo estimations of AT1 receptor numbers. Plasma renin activity, angiotensin II, and aldosterone were inversely related to changes in AT1 receptor binding. These results demonstrate, for the first time in vivo, that the renal AT1 receptor is inversely related to the activity of the renin angiotensin system, which may provide a compensatory mechanism to prevent inappropriate fluctuations in arterial BP. The ability to measure AT1 receptor binding in vivo has potential significance for clinical studies of AT1 receptors, because PET is a noninvasive imaging technique that is readily applicable in humans.

scholarly journals [68Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Emma Jussing ◽  
Li Lu ◽  
Jonas Grafström ◽  
Tetyana Tegnebratt ◽  
Fabian Arnberg ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Vascular Permeability ◽  
Ex Vivo ◽  
Circulatory System ◽  
Binding Domain ◽  
The Body ◽  
Emission Tomography ◽  
Albumin Binding ◽  
Positron Emission

Abstract Background Albumin is commonly used as a carrier platform for drugs to extend their circulatory half-lives and influence their uptake into tissues that have altered permeability to the plasma protein. The albumin-binding domain (ABD) protein, which binds in vivo to serum albumin with high affinity, has proven to be a versatile scaffold for engineering biopharmaceuticals with a range of binding capabilities. In this study, the ABD protein equipped with a mal-DOTA chelator (denoted ABY-028) was radiolabeled with gallium-68 (68Ga). This novel radiotracer was then used together with positron emission tomography (PET) imaging to examine variations in the uptake of the ABD-albumin conjugate with variations in endothelial permeability. Results ABY-028, produced by peptide synthesis in excellent purity and stored at − 20 °C, was stable for 24 months (end of study). [68Ga]ABY-028 could be obtained with labeling yields of > 80% and approximately 95% radiochemical purity. [68Ga]ABY-028 distributed in vivo with the plasma pool, with highest radioactivity in the heart ventricles and major vessels of the body, a gradual transport over time from the circulatory system into tissues and elimination via the kidneys. Early [68Ga]ABY-028 uptake differed in xenografts with different vascular properties: mean standard uptake values (SUVmean) were initially 5 times larger in FaDu than in A431 xenografts, but the difference decreased to 3 after 1 h. Cutaneously administered, vasoactive nitroglycerin increased radioactivity in the A431 xenografts. Heterogeneity in the levels and rates of increases of radioactivity uptake was observed in sub-regions of individual MMTV-PyMT mammary tumors and in FaDu xenografts. Higher uptake early after tracer administration could be observed in lower metabolic regions. Fluctuations in the increased permeability for the tracer across the blood-brain-barrier (BBB) direct after experimentally induced stroke were monitored by PET and the increased uptake was confirmed by ex vivo phosphorimaging. Conclusions [68Ga]ABY-028 is a promising new tracer for visualization of changes in albumin uptake due to disease- and pharmacologically altered vascular permeability and their potential effects on the passive uptake of targeting therapeutics based on the ABD protein technology.

Sign in / Sign up

Export Citation Format

Share Document